Eigen RadarScience
Analysis

RSM01 antibody withstands viral resistance in laboratory study

The experimental antibody RSM01 showed a high barrier to resistance in a peer-reviewed study of respiratory syncytial virus, a respiratory infection of particular concern in young children. Laboratory variants resistant to the antibody were uncommon and moderately resistant. The antibody also neutralised a panel of contemporary virus samples. These cell-culture findings concern viral susceptibility; protection in infants remains a separate clinical question.

Science··Midday
Frontal symmetrical view into a stainless-steel cell-culture incubator holding three groups of multi-well assay plates and tissue-culture flasks with coral-pink growth medium.

Resistance stayed moderate in cell culture

RSM01, an antibody being developed against respiratory syncytial virus (RSV), showed a high resistance barrier in laboratory research published in the peer-reviewed journal Nature Communications. RSV is a respiratory virus of particular concern in young children. Resistant variants appeared infrequently with RSM01 and their resistance remained moderate. The work measured viral susceptibility in cultured cells; protection in infants requires clinical research.[1], [2]

The candidate is a monoclonal antibody, a laboratory-developed antibody of one type, designed to remain active for an extended period. Its development programme focuses on low- and middle-income countries, where RSV imposes a substantial burden of infant illness and mortality. The earlier laboratory attempts to obtain resistant variants had been unsuccessful. The new investigation compared RSM01 with the licensed antibodies nirsevimab and palivizumab. Both comparators were associated with highly resistant variants in the laboratory comparison, while RSM01 showed the more limited resistance pattern.[1], [2]

Contemporary samples remained susceptible

Another part of the study looked at contemporary clinical isolates from Argentina, South Africa and the Netherlands. RSM01 neutralised all 30 samples in that panel, comprising 14 RSV-A and 16 RSV-B isolates. These are the two virus groups represented in the collection. The panel brought recently circulating viruses into the assessment alongside the laboratory strains used elsewhere in the work.[1]

The samples span three regions, but their limited number covers only part of worldwide viral diversity. The results establish activity against that particular panel. The investigation also examined resistant variants’ observable properties and genetic changes, linking the resistance findings with a separate assessment of how well the viruses grew.[1], [2]

Resistant variants gained no growth advantage

None of the resistant variants grew better than its parental virus, and one variant associated with RSM01 grew less well. Every resistant variant remained susceptible to at least one other antibody. Those findings concern growth and susceptibility in the experimental setting. Absolute neutralisation measurements can vary substantially between laboratories, so the study gives greater interpretive weight to comparisons made within the same setting.[1]

The authors discuss structural constraints where the antibody binds as a possible interpretation of the observed resistance barrier. Transmission, clinical benefit and the durability of resistance resilience during widespread use remain questions beyond the cell-culture measurements.[1]

References

  1. News sourceNature CommunicationsRSV antibody shows a high resistance barrier in laboratory tests↩1↩2↩3↩4↩5↩6
  2. News sourceScienmagRSM01 antibody resists viral escape in laboratory tests↩1↩2↩3